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Editorial on the Research Topic
Immunotherapy for Tumor in the Brain: Insights From—and For—Other Tumor Sites
tUMor iMMUNotHEraPY: CoMMoN GroUNd
Accelerating progress in tumor immunotherapy reflects a balance between what is particular to a 
given tumor and what cuts across tumor types and sites, including primary and metastatic brain 
tumors. Although there are tumor-specific differences, the epidermal growth factor receptor (EGFR) 
is an important target for both glioblastoma and non-small cell lung cancer, among others, making 
insight into basic EGFR biology broadly relevant (1). Indirect manipulation of the immune response 
acts even more broadly, with checkpoint inhibitors giving durable responses against the individual 
antigens expressed by multiple tumor types (2). Understanding of the nature of tumor antigen is still 
evolving. General insights into the practical requirements for specificity (3) and the importance of 
neo-antigens (2) complement identification of tumor-specific targets (4).
Insights into tumor biology show a similar mix of the general and the specific. For any therapy, 
the eventual outgrowth of therapy-resistant tumor is common. Although resistance mechanisms 
vary, a general insight applies: it is now appreciated how often the potential for resistance, whether 
as clones with pre-existing mutations or as alternative regulatory states, is already present within the 
original tumor (5–8). Also appreciated is the importance of interactions between individual tumors 
and their local micro-environment (9–11), including those that favor immunosuppression. In this 
case, many details are also common, with many of the same components, such as regulatory T cells 
(Tregs) or cytokines (IL-10, etc.), implicated in the brain as other sites (Dutoit et al.; Perng and Lim).
BraiN tUMor: liMitS aNd CoNCErNS
Given these shared properties, it might be expected that tumor in the brain would show the same 
benefit from immunotherapy as tumor at other sites. In practice, it has been difficult to show definite 
benefit for brain tumor patients. This does not necessarily mean that brain tumors are more intrac-
table. For primary brain tumors, there are practical limitations on clinical trials. The most common 
primary brain tumor in adults is glioblastoma (also referred to as glioblastoma multiforme or high-
grade glioma). Although it’s grim prognosis gives glioblastoma prominence in public awareness and 
as a research focus, among all tumors it is rare (12).
Brain metastases are far more common. They are characteristic of some of the most common 
primary tumors, including those of the lung and breast, and of the best-studied example of success-
ful immunotherapy, metastatic melanoma. As these and other tumors come under better control 
at other sites, brain metastases are increasingly important as a site of recurrence. Survival after 
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conventional therapies for brain metastases can be just a few 
months, and toxicity, especially after radiation therapy, is of great 
concern. Despite this background, patients with brain metastases 
have often been excluded from clinical trials (Cohen and Kluger). 
Reasons have ranged from pessimism, given the poor prognosis, 
to specific concerns about immunotherapy.
rEtHiNKiNG “PriVilEGE” aNd tHE 
Blood–BraiN BarriEr
A concern that has been relevant for all brain tumors, whether 
primary or metastatic, has been whether safe immunotherapy 
was even possible. A widespread, deeply entrenched assumption 
that the brain is, or should be, “immunologically privileged” 
was supported by awareness of detrimental responses, including 
autoimmune disease, such as multiple sclerosis, or a pathological 
response to neural virus. Fortunately, this concern is increasingly 
understood to be outdated (Huber and Irani).
From many contexts, especially work with neural viruses, it 
is clear that the immune response in the brain can be beneficial, 
is necessary, and, just as in other organs (3), is under regula-
tory control. Although, just as in other organs, a mis-regulated 
response can cause its own pathology, the immune response 
can safely control virus in the brain (13) (Huber and Irani; 
Huber et al.).
A related concern has been whether the blood–brain barrier 
(BBB) would prevent immune effectors from reaching brain 
tumor sites (14). In the normal brain parenchyma, passive entry 
of antibody protein is indeed blocked by the BBB. Nonetheless, 
antibody can affect the brain. The BBB is plastic; it changes as 
tumor grows. Indeed, leakage of immunoglobulin into the brain 
is a classic sign of pathology. The extent to which antibody can 
enter the brain, or accumulate, at sites of pathology, and the 
mechanisms by which even small amounts may be beneficial 
are of current interest for tumor, especially microscopic tumor 
(3, 14), and more broadly (15).
Although the same term is used, BBB has a different mean-
ing for effector cells (cytotoxic T cells, etc.) than for antibodies. 
Metabolically active, migratory cells are well able to enter the 
tissues, including the brain, if appropriate signals are present 
(Huber et al.) (13, 16). Indeed, precursors to antibody forming 
cells can enter the brain, and make antibody from within it. 
Precedent is seen in the life-long production, within the brain, 
of antibody to neural viruses (Huber et al.) (13); this potential 
has not yet been intentionally exploited against brain tumor (14).
WHErE WE arE
A more optimistic view of immunotherapy for the brain is 
consistent with accumulating experience with brain tumors, as 
described by the papers herein. The clearest benefit has been 
seen for brain metastases (Cohen and Kluger). Many approaches 
are also being taken for glioblastoma (Ampie et al.; Dutoit et al.; 
Van Gool; Yamanaka and Hayano), although the work is at an 
earlier stage. The immune response encompasses a multitude 
of effector cells, molecules, and mechanisms; although broadly 
shared, their balance and regulation vary (3) (Huber et al.; Perng 
and Lim; Dutoit et al.). As targets, the biology of glioblastoma is 
very different from that of most metastases (3, 14); the optimal 
immunotherapy strategy need not be the same.
Today, we have seen that the immune response is able to control 
human tumor, and that the response can be intentionally enhanced 
(2). The field is young. Not every patient benefits, many tumors 
recur, and often responses are not well-controlled. The papers 
herein illustrate growing appreciation that immunotherapy, its 
potential and its challenges, are just as relevant for the brain as 
for other sites. Achieving a balance between immunotherapy and 
autoimmunity is a general challenge, not only for tumors, and 
has been a special concern for the brain. As the brain’s relevance 
becomes accepted, insights gained from the brain and other sites 
should reinforce each other.
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